For years, the GLS Capital team has been a united front in designing litigation finance solutions for businesses and law firms.

Our principals rely on years of experience as underwriters at the world’s largest litigation finance providers and as litigators at elite law firms.


Adam Gill

Managing Director

Adam Gill is a founder and Managing Director at GLS Capital and leads patent-related investments.  Adam has evaluated hundreds of patent opportunities and has underwritten and managed hundreds of millions of dollars of litigation finance investments.  He has led cases and investments in which his clients and counterparties have obtained more than $700 million in settlements and verdicts.

Adam’s experience in litigation finance began in 2013 when he joined Gerchen Keller Capital, LLC (“GKC”) as its first employee and led its patent investment team as the firm grew from $100 million AUM into the world’s largest private fund focused on legal and regulatory risk in 2016, with $1.4 billion AUM. After GKC was acquired by Burford in December 2016, Adam served as a Principal at Burford.

Prior to joining GKC, Adam was a partner in the patent litigation group of Kirkland & Ellis LLP in Chicago. Before joining K&E in 2004, Adam was a litigator in the Silicon Valley office of Dechert LLP, where he practiced patent, trade secret, securities and antitrust litigation. Adam holds a J.D. from the University of California-Hastings College of the Law and a B.A. from the University of South Carolina.

Jamison Lynch

Managing Director

Jamison “Jamie” Lynch is a founder and Managing Director at GLS. Jamie leads GLS investments in life sciences and special situations.

Jamie is a former Principal at GKC where he led the firm’s life sciences investments, including those involving patent litigation.  Jamie joined GKC in 2016 and assumed management of the firm’s investments and underwriting for matters involving product development, regulatory approval, and litigation regarding medical devices, pharmaceutical products, health care and other life sciences matters.  After GKC was acquired by Burford in December 2016, Jamie served as a Principal at Burford.

Prior to joining GKC, Jamie co-led the global patent litigation team at Gilead Sciences, Inc. (“Gilead”). At Gilead, Jamie led global litigation strategy and execution, including Hatch-Waxman litigation, for products representing $19 billion in annual revenue.

Prior to joining Gilead, Jamie was a partner at Mayer Brown, where he actively involved in pharmaceutical patent litigation, patent prosecution and due diligence in the firm’s Chicago and Frankfurt offices. Before Mayer Brown, Jamie represented generic companies in Hatch-Waxman disputes at Schiff Hardin and Leydig, Voit & Mayer. Jamie holds a J.D. and B.S. (mechanical engineering, with additional significant coursework in chemistry) from the University of Wisconsin.

David Spiegel

Managing Director

David Spiegel is a founder and Managing Director of GLS.  David leads commercial litigation and arbitration-related investing at GLS, having previously led investment teams at the world’s two largest litigation finance firms.

David has deep experience originating, underwriting, and managing litigation finance investments related to claims of breach of contract, fraudulent conveyance, antitrust, judgment enforcement, and investor-state arbitration, among others. David also has consulted and testified as an expert in high-profile disputes regarding the valuation of litigation assets.

Prior to entering litigation finance, David was a litigator in the Chicago office of Kirkland & Ellis LLP, where he represented clients in a wide array of industries.  He holds a J.D. from the University of Pennsylvania Law School, an MSc from the London School of Economics, and a B.A. from Northwestern University.